Structure Therapeutics (GPCR) Cash from Investing Activities (2022 - 2026)

Structure Therapeutics' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$496.9 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 1560.19% year-over-year to -$496.9 million in Q1 2026; TTM through Mar 2026 was -$441.2 million, a 35.21% decrease from a year earlier, with the FY2025 full-year figure at $89.8 million, up 125.02% from the prior year.
• Cash from Investing Activities declined to -$496.9 million in Q1 2026 per GPCR's latest filing, from $56.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $56.1 million in Q4 2025 and bottomed at -$496.9 million in Q1 2026.
• The 5-year median for Cash from Investing Activities is -$16.7 million (2022), against an average of -$64.5 million.
• Across the five-year window, Cash from Investing Activities tumbled 1847.84% in 2023 and jumped 2300.07% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at $10.3 million in 2022, then tumbled by 1847.84% to -$180.7 million in 2023, then soared by 118.39% to $33.2 million in 2024, then soared by 68.93% to $56.1 million in 2025, then slumped by 985.19% to -$496.9 million in 2026.
• Per Business Quant, the three latest GPCR Cash from Investing Activities figures stand at -$496.9 million (Q1 2026), $56.1 million (Q4 2025), and -$49.3 million (Q3 2025).